FCMI
Foresite Capital Management IV Portfolio holdings
AUM
$124M
This Quarter Return
-9.15%
1 Year Return
-24.36%
3 Year Return
+1.86%
5 Year Return
+16.17%
10 Year Return
–
AUM
$109M
AUM Growth
+$109M
(-29%)
Cap. Flow
-$17.9M
Cap. Flow
% of AUM
-16.47%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
–
Reduced
1
Closed
1
Top Buys
No buys this quarter
Top Sells
| 1 |
Syndax Pharmaceuticals
SNDX
|
$16.8M |
| 2 |
Kura Oncology
KURA
|
$1.07M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Pharvaris
PHVS
$1.39B
| $84.3M | 77.49% | 4,397,881 | – | – |
|
|
2
Kura Oncology
KURA
$686M
| $15M | 13.83% | 1,726,882 -123,065 | -7% | -$1.07M |
|
3
Lyell Immunopharma
LYEL
$213M
| $5.33M | 4.9% | 8,325,000 | – | – |
|
4
Relay Therapeutics
RLAY
$619M
| $4.12M | 3.79% | 1,000,000 | – | – |
|
|
5
Syndax Pharmaceuticals
SNDX
$1.41B
| – | – | -875,000 | Closed | -$16.8M |
|